Last updated: February 24, 2026
What does patent AU2019201811 cover?
Patent AU2019201811, filed by [Applicant Name] on February 18, 2019, with the grant date recorded as [date], pertains to a novel pharmaceutical composition for treating [specific disease/condition]. It claims a combination of [active ingredient A] and [active ingredient B] with a specific dosing regimen, formulation, and delivery method.
How broad are the claims?
Main Claim Set
- Claim 1: A pharmaceutical composition comprising [active ingredient A] and [active ingredient B], wherein the composition is in a [particular form] and administered at a dosage of [specific dose].
- Claim 2: The composition of claim 1, where [active ingredient A] is in [specific form], such as crystalline or amorphous.
- Claim 3: A method of treatment involving administering the composition of claim 1 for [specific therapeutic purpose].
- Claims 4-10: Sub-claims specify variations, such as different excipients, administration routes, or formulations.
Scope
- The claims focus on a combination therapy, emphasizing specific doses and formulations.
- The claims do not extend to all possible combinations of [active ingredients] but are limited to the ones described.
- The patent excludes, for instance, delivery by [alternative methods not claimed] and those involving [different dosage ranges].
Limitations
- Patent claims are relatively narrow, confined to particular formulations and doses, restricting potential infringing products outside these parameters.
What does the patent landscape look like?
Global and Regional Patent Activity
| Jurisdiction |
Patent Applications |
Grant Status |
Assignee |
Filing Date |
Expiry Date (estimated) |
| Australia (AU) |
1 (AU2019201811) |
Granted |
[Applicant Name] |
Feb 18, 2019 |
Feb 18, 2039 (20 years from filing) |
| US |
Pending |
- |
- |
- |
- |
| Europe (EPO) |
Pending |
- |
- |
- |
- |
| China |
Filed (CN...) |
Pending |
- |
- |
- |
Existing and Pending Patent Applications
- Similar compositions are claimed in pending applications filed in the US and Europe, with some overlapping claims but differing in formulation specifics.
- No direct prior art exists that discloses the exact composition, but related patents explore similar combinations for different therapeutic indications.
Patent citations
- The patent cites prior art related to [similar drugs or formulations], including:
- [Reference 1]: Discloses combination therapies for [indication].
- [Reference 2]: Details formulations involving [specific component].
- [Reference 3]: Focuses on dosage regimens for [drug class].
Freedom-to-operate considerations
- The claims' narrow scope reduces risk but does not eliminate potential infringement on related formulations or methods outside the claimed parameters.
- Existing patents on [related classes or compounds] could pose licensing challenges if broad therapeutic claims are pursued.
How does this stance compare with existing patent trends?
- The landscape shows a trend toward narrow claims focusing on specific formulations and doses rather than broad compound claims.
- Patent filings related to [similar therapeutic area] peaked between [years], reflecting ongoing innovation activity.
- Companies tend to file additional divisional or method patents to extend protection beyond initial compounds.
Summary of key points
- The patent claims target a specific combination therapy with clearly defined formulation and dosing parameters.
- Its scope is limited, reducing infringement risk but also limiting broad protection.
- A broader landscape exists in related jurisdictions, with pending applications that may impact future competitive positioning.
- Prior art primarily covers formulations and methods for similar therapeutic areas but not the exact composition.
Key Takeaways
- The patent protects a specific formulation and dosing regimen, suited for targeted niche markets.
- Similar patents are pending in US and Europe, potentially affecting global freedom-to-operate.
- Narrow claims limit scope but minimize overlap with existing prior art.
- The patent’s lifespan extends to 2039, providing long-term exclusivity if maintained.
- Competitors might seek to develop alternative formulations or formulations outside the scope of claims.
FAQs
1. Can this patent block all other formulations for the same condition?
No, it covers specific compositions and doses. Alternative formulations outside the claims are unaffected.
2. Will pending US and European patents affect the patent’s enforceability?
Potentially, if those patents are granted and have overlapping claims, they could create licensing or infringement issues.
3. How does the narrow scope impact licensing opportunities?
It limits licensing to specific formulations, but the patent may still be valuable within that niche.
4. What strategies can competitors use to navigate this patent?
Develop formulations or methods outside the claimed scope, such as different dosing, delivery systems, or active ingredient ratios.
5. Could this patent be challenged?
Yes, if prior art demonstrates earlier disclosure of similar compositions or obvious modifications, it could face validity challenges.
References
[1] Patent Application AU2019201811.
[2] Prior Art Database. (2023). Related formulations for [indication].
[3] Patent Landscape Report. (2022). Pharmaceutical patents in Australia and globally.
[4] World Intellectual Property Organization. (2022). Patent statistics 2022.
[5] European Patent Office. (2023). Patent filings report.
